Advertisement
Screener

Assembly Biosciences, Inc. (ASMB) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Assembly Biosciences, Inc. Comprehensive Income

Assembly Biosciences, Inc. (ASMB) reported Comprehensive Income of -$4.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Income Statement

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13

  • Assembly Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$4.11M.
  • Assembly Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$9.41M.
  • Assembly Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $22.14M.
  • Assembly Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$9.01M.
  • Assembly Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$5.95M.
  • Assembly Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$40.31M.
  • Assembly Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$60.51M.
  • Assembly Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$93.48M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2026-06-30-$4.11M
10-Q · filed 2026-08-13
-$13.52M
10-Q · filed 2026-08-13
$8.62M
derived: sum of 3 quarters · filed 2026-08-13
-$386.00K
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$9.41M
10-Q · filed 2026-05-07
$12.73M
derived: sum of 2 quarters · filed 2026-05-07
$3.73M
derived: sum of 3 quarters · filed 2026-05-07
-$6.50M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$22.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
$13.13M
derived: sum of 2 quarters · filed 2026-03-19
$2.91M
derived: sum of 3 quarters · filed 2026-08-13
-$5.95M
10-K · filed 2026-03-19
2025-09-30-$9.01M
10-Q · filed 2025-11-10
-$19.23M
derived: sum of 2 quarters · filed 2026-08-13
-$28.09M
10-Q · filed 2025-11-10
-$38.48M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$10.22M
10-Q · filed 2026-08-13
-$19.08M
10-Q · filed 2026-08-13
-$29.47M
derived: sum of 3 quarters · filed 2026-08-13
-$38.95M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$8.86M
10-Q · filed 2026-05-07
-$19.25M
derived: sum of 2 quarters · filed 2026-05-07
-$28.73M
derived: sum of 3 quarters · filed 2026-05-07
-$39.93M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$10.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$19.87M
derived: sum of 2 quarters · filed 2026-03-19
-$31.07M
derived: sum of 3 quarters · filed 2026-03-19
-$40.31M
10-K · filed 2026-03-19
2024-09-30-$9.48M
10-Q · filed 2025-11-10
-$20.68M
derived: sum of 2 quarters · filed 2025-11-10
-$29.92M
10-Q · filed 2025-11-10
-$40.69M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30-$11.21M
10-Q · filed 2025-08-06
-$20.44M
10-Q · filed 2025-08-06
-$31.21M
derived: sum of 3 quarters · filed 2025-08-06
-$45.58M
derived: sum of 4 quarters · filed 2025-08-06
2024-03-31-$9.23M
10-Q · filed 2025-05-08
-$20.00M
derived: sum of 2 quarters · filed 2025-05-08
-$34.37M
derived: sum of 3 quarters · filed 2025-05-08
-$51.08M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31-$10.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
-$25.14M
derived: sum of 2 quarters · filed 2025-03-20
-$41.85M
derived: sum of 3 quarters · filed 2025-03-20
-$60.51M
10-K · filed 2025-03-20
2023-09-30-$14.37M
10-Q · filed 2024-11-07
-$31.08M
derived: sum of 2 quarters · filed 2024-11-07
-$49.74M
10-Q · filed 2024-11-07
-$71.94M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$16.71M
10-Q · filed 2024-08-08
-$35.37M
10-Q · filed 2024-08-08
-$57.57M
derived: sum of 3 quarters · filed 2024-08-08
-$80.71M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$18.66M
10-Q · filed 2024-05-08
-$40.86M
derived: sum of 2 quarters · filed 2024-05-08
-$64.00M
derived: sum of 3 quarters · filed 2024-05-08
-$88.56M
derived: sum of 4 quarters · filed 2024-05-08
2022-12-31-$22.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
-$45.34M
derived: sum of 2 quarters · filed 2024-03-28
-$69.90M
derived: sum of 3 quarters · filed 2024-03-28
-$93.48M
10-K · filed 2024-03-28
2022-09-30-$23.15M
10-Q · filed 2023-11-08
-$47.70M
derived: sum of 2 quarters · filed 2023-11-08
-$71.28M
10-Q · filed 2023-11-08
-$131.66M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30-$24.55M
10-Q · filed 2023-08-09
-$48.13M
10-Q · filed 2023-08-09
-$108.52M
derived: sum of 3 quarters · filed 2023-08-09
-$127.34M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$23.58M
10-Q · filed 2023-05-04
-$83.97M
derived: sum of 2 quarters · filed 2023-05-04
-$102.79M
derived: sum of 3 quarters · filed 2023-05-04
-$126.38M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31-$60.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22
-$79.21M
derived: sum of 2 quarters · filed 2023-03-22
-$102.80M
derived: sum of 3 quarters · filed 2023-03-22
-$130.00M
10-K · filed 2023-03-22
2021-09-30-$18.82M
10-Q · filed 2022-11-08
-$42.41M
derived: sum of 2 quarters · filed 2022-11-08
-$69.62M
10-Q · filed 2022-11-08
-$109.15M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$23.60M
10-Q · filed 2022-08-09
-$50.80M
10-Q · filed 2022-08-09
-$90.33M
derived: sum of 3 quarters · filed 2022-08-09
-$93.94M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$27.20M
10-Q · filed 2022-05-12
-$66.73M
derived: sum of 2 quarters · filed 2022-05-12
-$70.34M
derived: sum of 3 quarters · filed 2022-05-12
-$62.88M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$39.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11
-$43.14M
derived: sum of 2 quarters · filed 2022-03-11
-$35.68M
derived: sum of 3 quarters · filed 2022-03-11
-$62.22M
10-K · filed 2022-03-11
2020-09-30-$3.61M
10-Q · filed 2021-11-04
$3.85M
derived: sum of 2 quarters · filed 2021-11-04
-$22.69M
10-Q · filed 2021-11-04
-$49.77M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30$7.46M
10-Q · filed 2021-08-05
-$19.08M
10-Q · filed 2021-08-05
-$46.16M
derived: sum of 3 quarters · filed 2021-08-05
-$71.17M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31-$26.54M
10-Q · filed 2021-05-06
-$53.62M
derived: sum of 2 quarters · filed 2021-05-06
-$78.63M
derived: sum of 3 quarters · filed 2021-05-06
-$97.08M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31-$27.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
-$52.09M
derived: sum of 2 quarters · filed 2021-02-25
-$70.54M
derived: sum of 3 quarters · filed 2021-02-25
-$97.49M
10-K · filed 2021-02-25
2019-09-30-$25.01M
10-Q · filed 2020-11-05
-$43.46M
derived: sum of 2 quarters · filed 2020-11-05
-$70.41M
10-Q · filed 2020-11-05
-$96.56M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30-$18.45M
10-Q · filed 2020-08-05
-$45.40M
10-Q · filed 2020-08-05
-$71.55M
derived: sum of 3 quarters · filed 2021-02-25
-$93.07M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31-$26.94M
10-Q · filed 2020-05-08
-$53.10M
derived: sum of 2 quarters · filed 2021-02-25
-$74.61M
derived: sum of 3 quarters · filed 2021-02-25
-$101.33M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31-$26.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
-$47.67M
derived: sum of 2 quarters · filed 2021-02-25
-$74.39M
derived: sum of 3 quarters · filed 2021-02-25
-$90.71M
10-K · filed 2021-02-25
2018-09-30-$21.52M
10-Q · filed 2019-11-07
-$21.52M
10-Q · filed 2018-11-08
-$48.24M
derived: sum of 2 quarters · filed 2019-11-07
-$64.55M
10-Q · filed 2019-11-07
-$64.55M
10-Q · filed 2018-11-08
-$67.56M
derived: sum of 4 quarters · filed 2020-03-04
2018-06-30-$26.72M
10-Q · filed 2019-08-05
-$26.72M
10-Q · filed 2018-08-08
-$43.03M
10-Q · filed 2019-08-05
-$43.03M
10-Q · filed 2018-08-08
-$46.05M
derived: sum of 3 quarters · filed 2020-03-04
-$58.31M
derived: sum of 4 quarters · filed 2020-03-04
2018-03-31-$16.32M
10-Q · filed 2019-05-09
-$16.32M
10-Q · filed 2018-05-07
-$19.33M
derived: sum of 2 quarters · filed 2020-03-04
-$31.59M
derived: sum of 3 quarters · filed 2020-03-04
-$45.06M
derived: sum of 4 quarters · filed 2020-03-04
2017-12-31-$3.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04
-$15.27M
derived: sum of 2 quarters · filed 2020-03-04
-$28.75M
derived: sum of 3 quarters · filed 2020-03-04
-$42.60M
10-K · filed 2020-03-04
-$42.60M
10-K · filed 2018-03-08
2017-09-30-$12.26M
10-Q · filed 2018-11-08
-$25.73M
derived: sum of 2 quarters · filed 2018-11-08
-$39.59M
10-Q · filed 2018-11-08
-$50.90M
derived: sum of 4 quarters · filed 2019-02-28
2017-06-30-$13.47M
10-Q · filed 2018-08-08
-$27.33M
10-Q · filed 2018-08-08
-$38.64M
derived: sum of 3 quarters · filed 2019-02-28
-$50.21M
derived: sum of 4 quarters · filed 2019-02-28
2017-03-31-$13.85M
10-Q · filed 2018-05-07
-$25.16M
derived: sum of 2 quarters · filed 2019-02-28
-$36.74M
derived: sum of 3 quarters · filed 2019-02-28
-$46.98M
derived: sum of 4 quarters · filed 2019-02-28
2016-12-31-$11.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28
-$22.88M
derived: sum of 2 quarters · filed 2019-02-28
-$33.12M
derived: sum of 3 quarters · filed 2019-02-28
-$44.04M
10-K · filed 2019-02-28
-$44.04M
10-K · filed 2017-03-02
2016-09-30-$11.57M
10-Q · filed 2017-11-01
-$21.81M
derived: sum of 2 quarters · filed 2017-11-01
-$32.73M
10-Q · filed 2017-11-01
-$40.91M
derived: sum of 4 quarters · filed 2018-03-08
2016-06-30-$10.24M
10-Q · filed 2017-08-09
-$21.16M
10-Q · filed 2017-08-09
-$29.34M
derived: sum of 3 quarters · filed 2018-03-08
-$36.21M
derived: sum of 4 quarters · filed 2018-03-08
2016-03-31-$10.92M
10-Q · filed 2017-05-08
-$19.10M
derived: sum of 2 quarters · filed 2018-03-08
-$25.97M
derived: sum of 3 quarters · filed 2018-03-08
-$33.05M
derived: sum of 4 quarters · filed 2018-03-08
2015-12-31-$8.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
-$15.05M
derived: sum of 2 quarters · filed 2018-03-08
-$22.13M
derived: sum of 3 quarters · filed 2018-03-08
-$29.28M
10-K · filed 2018-03-08
2015-09-30-$6.87M
10-Q · filed 2016-11-09
-$13.95M
derived: sum of 2 quarters · filed 2016-11-09
-$21.09M
10-Q · filed 2016-11-09
-$27.32M
derived: sum of 4 quarters · filed 2017-03-02
2015-06-30-$7.08M
10-Q · filed 2016-08-09
-$14.22M
10-Q · filed 2016-08-09
-$20.45M
derived: sum of 3 quarters · filed 2017-03-02
-$31.47M
derived: sum of 4 quarters · filed 2017-03-02
2015-03-31-$7.14M
10-Q · filed 2016-05-10
-$13.37M
derived: sum of 2 quarters · filed 2017-03-02
-$24.39M
derived: sum of 3 quarters · filed 2017-03-02
-$26.86M
derived: sum of 4 quarters · filed 2017-03-02
2014-12-31-$6.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02
-$17.25M
derived: sum of 2 quarters · filed 2017-03-02
-$19.72M
derived: sum of 3 quarters · filed 2017-03-02
-$23.79M
10-K · filed 2017-03-02
2014-09-30-$11.02M
10-Q · filed 2015-11-09
-$13.49M
derived: sum of 2 quarters · filed 2015-11-09
-$17.56M
10-Q · filed 2015-11-09
2014-06-30-$2.47M
10-Q · filed 2015-08-13
-$6.54M
10-Q · filed 2015-08-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
ARVINAS, INC. (ARVN)United States$0.510B58.38
Evolus, Inc. (EOLS)United States$0.519B-13.32
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53